Drugs / OC514
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05264038 | Mar → Sep 2022 | — | Oncocross Australia Pty Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OC514 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05264038 ↗ |
| Route | Oral | “single and multiple oral doses of OC514” NCT05264038 ↗ |